Definium Therapeutics' LSD-Based Treatment Shows Promise in Anxiety Reduction
Definium Therapeutics (DFTX) reported that its LSD-based treatment significantly reduced anxiety symptoms, with patients showing a 9.8-point improvement on the Hamilton Anxiety Rating Scale over 12 weeks compared to a 4.7-point improvement for those receiving a placebo. The results were notable due to their rapid onset and substantial impact relative to standard benchmarks. The announcement came as DFTX shares had already surged by 190% in 2026, reflecting strong investor interest in the psychedelic therapy space. This latest development has further fueled optimism around the company's pipeline and potential for regulatory approval or commercialization of its treatment. Market analysts are watching closely to see how this data influences broader sentiment toward psychedelics-based therapies and whether it could lead to increased investment or partnerships with larger pharmaceutical firms.
Tickers: $DFTX